TABLE 2.
Changing antimicrobial resistance in different serogroup between 2012 and 2019.
| Antimicrobials | 2012 | 2019 | P value | OR | 95% CI |
| Serogroup B | |||||
| MDR | 11.2% (11/98) | 32% (32/100) | <0.001 | 3.72 | 1.74−7.91 |
| Ceftriaxone | 5.1% (5/98) | 15% (15/100) | 0.021 | 3.28 | 1.14−9.41 |
| Ciprofloxacin | 1% (1/98) | 27.3% (27/99) | <0.001 | 36.3 | 4.83−273.95 |
| Ampicillin | 53.1% (52/98) | 43% (43/100) | 0.157 | 1.49 | 0.85−2.62 |
| TMP-SMX | 26.5% (26/98) | 35% (35/100) | 0.197 | 0.671 | 0.365−1.232 |
| Ertapenem | 0% (0/98) | 1% (1/100) | 1.000 | NA | NA |
| Imipenem | 0% (0/98) | 2% (2/100) | 0.498 | NA | NA |
| Serogroup C1 | |||||
| MDR | 10% (2/20) | 34.5% (10/29) | 0.089 | 4.73 | 0.91−24.64 |
| Ceftriaxone | 0% (0/20) | 20.7% (6/29) | 0.069 | NA | NA |
| Ciprofloxacin | 0% (0/20) | 44.8% (13/29) | <0.001 | NA | NA |
| TMP-SMX | 26.3% (5/19) | 32.1% (9/28) | 0.668 | 0.754 | 0.20−2.74 |
| Ampicillin | 47.4% (9/19) | 44.8% (13/29) | 0.863 | 1.10 | 0.34−3.53 |
| Ertapenem | 0% (0/19) | 3.4% (1/29) | 1.000 | NA | NA |
| Imipenem | 0% (0/19) | 3.4% (1/29) | 1.000 | NA | NA |
| Serogroup C2 | |||||
| MDR | 8.9% (4/45) | 16.1% (9/56) | 0.284 | 1.96 | 0.56−6.85 |
| Ceftriaxone | 4.4% (2/45) | 5.4% (3/56) | 1.000 | 1.21 | 0.19−7.61 |
| Ciprofloxacin | 2.2% (1/45) | 19.6% (11/56) | 0.007 | 10.75 | 1.33−86.85 |
| TMP-SMX | 31.1% (14/45) | 14.3% (8/56) | 0.042 | 2.70 | 1.01−7.21 |
| Ampicillin | 62.6% (28/45) | 23.2% (13/56) | <0.001 | 5.44 | 2.29−12.93 |
| Ertapenem | 0% (0/45) | 0% (0/56) | NA | NA | NA |
| Imipenem | 0% (0/45) | 0% (0/56) | NA | NA | NA |
| Serogroup D | |||||
| MDR | 14.2% (22/155) | 31.4% (58/185) | <0.001 | 2.76 | 1.59−4.77 |
| Ceftriaxone | 5.2% (8/155) | 15.1% (28/185) | 0.003 | 3.27 | 1.44−7.42 |
| Ciprofloxacin | 2.6% (4/155) | 27.6% (51/185) | <0.001 | 14.36 | 5−40.8 |
| TMP-SMX | 27.7% (43/155) | 30.4% (56/184) | 0.587 | 0.878 | 0.548−1.406 |
| Ampicillin | 45.8% (71/155) | 43.2% (80/185) | 0.636 | 1.10 | 0.72−1.70 |
| Ertapenem | 0% (0/155) | 0% (0/185) | NA | NA | NA |
| Imipenem | 0% (0/155) | 0.5% (1/185) | 1.000 | NA | NA |
| Serogroup E | |||||
| MDR | 12.5% (5/40) | 31.6% (18/57) | 0.030 | 3.23 | 1.08−9.61 |
| Ceftriaxone | 0% (0/40) | 14% (8/57) | 0.019 | NA | NA |
| Ciprofloxacin | 2.5% (1/40) | 19.6% (19/57) | <0.001 | 19.5 | 2.48−152.98 |
| TMP-SMX | 27.5% (11/40) | 28.1% (16/57) | 0951 | 0.972 | 0.394−2.398 |
| Ampicillin | 42.5% (17/40) | 38.6% (22/57) | 0.700 | 1.17 | 0.51−2.67 |
| Ertapenem | 0% (0/40) | 0% (0/57) | NA | NA | NA |
| Imipenem | 0% (0/40) | 0% (0/57) | NA | NA | NA |
MDR, multi-drug resistance, resistant to ≥3 drug classes; TMP-SMX, trimethoprim/sulfamethoxazole; OR, odds ratio; CI, confidence interval; NA, not applicable.